Loading
Breast oncologist who led MONARCH 3 and studies how genetics shapes response to endocrine therapy.
Matthew Goetz is Professor of Oncology and Pharmacology and Co-leader of the Women's Cancer Program at Mayo Clinic. A breast medical oncologist and pharmacologist specialising in pharmacogenomics and CDK4/6 inhibitors, he was principal investigator of MONARCH 3, the trial of abemaciclib as initial therapy for advanced breast cancer, and of tamoxifen pharmacogenomics work on how genetics shapes response to endocrine therapy. His papers report MONARCH 3 in the Journal of Clinical Oncology and the final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor in HR-positive, HER2-negative advanced breast cancer in Annals of Oncology. He co-leads the breast cancer programme at Mayo Clinic, working on CDK4/6 and the oestrogen receptor.
| Title | Journal | Year |
|---|---|---|
| MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer | Journal of Clinical Oncology | 2017 |
| Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3 | Annals of Oncology | 2024 |
Shares Abemaciclib, CDK4/6, Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
Shares CDK4/6, Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
Shares Abemaciclib, CDK4/6, HR-positive / HER2-negative breast cancer.
Shares CDK4/6, Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
Shares Abemaciclib, CDK4/6.
Shares Abemaciclib, Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
Shares Abemaciclib, CDK4/6, Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.